![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Luminex Earns U.S. Funding for COVID-19/Flu/RSV Multi-Test
Luminex Earns U.S. Funding for COVID-19/Flu/RSV Multi-Test
![Luminex logo](https://www.fdanews.com/ext/resources/test/Device_Images5/Luminex_Logo.gif?t=1614197019&width=430)
Luminex has been granted $11.3 million in funding from HHS’ Biomedical Advanced Research and Development Authority (BARDA) to support its efforts to develop and validate a multi-panel COVID-19 test.
The respiratory panel combines influenza A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 targets to distinguish between the viruses and will deliver results in less than two hours, Luminex said. The company’s original SARS-CoV-2 assay was granted Emergency Use Authorization by the FDA last year and also received support from BARDA.
The test is being designed to run on Luminex’s ARIES real-time polymerase chain reaction (RT-PCR) automated molecular diagnostic platforms.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct